Multiple Myeloma

Challenges and Opportunities
  • Douglas Joshua
  • Ross Brown
  • P. Joy Ho
Part of the Methods in Molecular Medicine™ book series (MIMM, volume 113)


Multiple myeloma (MM) is a B-cell neoplasm in which malignant plasma cells accumulate in the bone marrow and produce lytic bone lesions and excessive amounts of a monoclonal protein (usually an immunoglobulin of the IgG or IgA type or free light chain). Approximately 14,000 new cases of MM are diagnosed each year in the United States, and the disease accounts for approx 1.9% of all cancer-related deaths (1,2). Despite significant advances in therapy, the disease remains essentially incurable. The therapy of choice in younger patients is currently high-dose therapy with autologous stem cell transplantation; however, a range of novel therapeutic options have recently become available, creating new opportunities for clinical investigation. The major challenge facing clinicians is to determine which of these new agents or which combination of agents will prove to be the most effective and result in a cure for even a small proportion of patients.


Multiple Myeloma Autologous Stem Cell Transplantation Free Light Chain Monoclonal Protein Malignant Plasma Cell 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Greenlee R. T., Hill-Harmon M. B., Murray T., and Thun M. (2001) Cancer statistics, 2001. CA Cancer J. Clin. 2001 51, 15–36.PubMedCrossRefGoogle Scholar
  2. 2.
    Ries L. A. G., Eisner M. P., and Kosary C. L. (2002) SEER Cancer Statistics Review, 1973–1999. National Cancer Institute, Bethesda, MD.Google Scholar
  3. 3.
    Barillé-Nion S., Barlogie B., Bataille R., et al. (2003) Advances in biology and therapy of multiple myeloma. Hematology (Am. Soc. Hematol. Educ. Program) 2003, 248–278.Google Scholar
  4. 4.
    Richardson P., Schlossman R., Weller E., et al. (2002) Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood 100, 3063–3067.PubMedCrossRefGoogle Scholar
  5. 5.
    Richardson P. G., Barlogie B., Berenson J., et al. (2003) A phase 2 study of bortezomib in relapsed, refractory myeloma. N. Engl. J. Med. 348, 2609–2617.PubMedCrossRefGoogle Scholar
  6. 6.
    Santucci R., Mackley P. A., Sebti S., and Alsina M. (2003) Farnesyltransferase inhibitors and their role in the treatment of multiple myeloma. Cancer Control 10, 384–387.PubMedGoogle Scholar
  7. 7.
    Liu Q. and Gazitt Y. (2003) Potentiation of dexamethasone-, paclitaxel-, and Ad-p53-induced apoptosis by Bcl-2 antisense oligodeoxynucleotides in drugresistant multiple myeloma cells. Blood 101, 4105–4114.PubMedCrossRefGoogle Scholar
  8. 8.
    Trudel S., Ely S., Farooqi Y., Affer M., Robbiani D. F., and Bergsagel P. (2004) Inhibition of fibroblast growth factor receptor 3 induces differentiation and apoptosis in t(4;14) myeloma. Blood 103, 3521–3528.PubMedCrossRefGoogle Scholar
  9. 9.
    Podar K., Catley L. P., Tai Y. T., et al. (2004) The pan-inhibitor of VEGF receptors GW654652 blocks growth and migration of multiple myeloma cells in the bone marrow microenvironment. Blood 103, 3474–3479.PubMedCrossRefGoogle Scholar
  10. 10.
    Facon T., Avet-Loiseau H., Guillerm G., et al. (2001) Chromosome 13 abnormalities identified by FISH analysis and serum beta2-microglobulin produce a powerful myeloma staging system for patients receiving high-dose therapy. Blood 97, 1566–1571.PubMedCrossRefGoogle Scholar
  11. 11.
    Desikan R., Barlogie B., Sawyer J., et al. (2000) Results of high-dose therapy for 1000 patients with multiple myeloma: durable complete remissions and superior survival in the absence of chromosome 13 abnormalities. Blood 95, 4008–4010.PubMedGoogle Scholar
  12. 12.
    Zhan F., Tian E., Bumm K., Smith R., Barlogie B., and Shaughnessy J., Jr. (2003) Gene expression profiling of human plasma cell differentiation and classification of multiple myeloma based on similarities to distinct stages of late-stage B-cell development. Blood 101, 1128–1140.PubMedCrossRefGoogle Scholar

Copyright information

© Humana Press Inc. 2005

Authors and Affiliations

  • Douglas Joshua
    • 1
  • Ross Brown
    • 2
  • P. Joy Ho
    • 3
  1. 1.Institute of HaematologyRoyal Prince Alfred HospitalSydneyAustralia
  2. 2.Institute of HaematologyRoyal Prince Alfred HospitalSydneyAustralia
  3. 3.Institute of HaematologyRoyal Prince Alfred HospitalSydneyAustralia

Personalised recommendations